Pulmonary delivery of monoclonal antibodies: challenges, limitations,and modern formulation strategies

Czech version

Authors: Paula Čermáková ¹; Juraj Piešťanský ^1,2
Authors‘ workplace: Katedra galenickej farmácie, Farmaceutická fakulta, Univerzita Komenského, Bratislava ¹; Toxikologické a antidopingové centrum, Farmaceutická fakulta, Univerzita Komenského, Bratislava ²
Published in: Čes. slov. Farm., 2026; 75, 101-107
Category: REVIEW ARTICLES
doi: https://doi.org/10.36290/csf.2026.018

Overview

Biopharmaceuticals, particularly monoclonal antibodies, represent a key therapeutic class in modern pharmacotherapy for the treatment of autoimmune, inflammatory, oncological, and rare diseases. Despite their high efficacy and specificity, their clinical use is largely limited to parenteral administration, which may negatively affect patient comfort and long-term treatment adherence. In recent years, the inhalation route of administration has emerged as a promising, non-invasive alternative, especially for respiratory diseases. This is due to the large absorptive surface area of the lungs, their rich vascularization, and the possibility of achieving high local drug concentrations while minimizing systemic adverse effects.

This review summarizes and critically evaluates current knowledge and emerging trends in the field of inhaled monoclonal antibodies. The text focuses on the specific features of pulmonary physiology, as well as the anatomical, physiological, and immunological barriers influencing the deposition, stability, and absorption of biological therapeutics. Particular attention is given to advanced formulation strategies aimed at improving pulmonary retention and the systemic bioavailability of protein-based drugs. Inhaled administration of biologics may significantly expand the therapeutic potential of monoclonal antibodies in the future and contribute to more effective and targeted treatment strategies.

Keywords:

Lungs – Monoclonal antibodies – inhalation delivery route – formulations

Sources

1. Kaur H. Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development. Crit Rev Biotechnol. 2021;41 : 300-315.

2. Cao SJ, Lv ZQ, Guo S, et al. An update –⁠ Prolonging the action of protein and peptide drugs. J Drug Deliv Sci Technol. 2021;61 : 102124.

3. Crescioli S, Kaplon H, Chenoweth A, et al. Antibodies to watch in 2026. MAbs. 18 : 2614669.

4. Zinn S, Vazquez-Lombardi R, Zimmermann C, et al. Advances in antibody-based therapy in oncology. Nat Cancer. 2023;4 : 165-180.

5. AstraZeneca. Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD [Internet]. AstraZeneca; 2026 [cited 2026 Apr 13]. Available from: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2026/tozorakimab-met-primary-endpoint-in-oberon-titania-phase-iii-trials-in-patients-with-copd.html

6. Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: The complex interplay of pulmonary kinetic processes. Can Respir J. 2018;2018 : 2732017.

7. Respaud R, Vecellio L, Diot P, et al. Nebulization as a delivery method for mAbs in respiratory diseases. Expert Opin Drug Deliv. 2015;12 : 1027-1039.

8. Li M, Kroetz DL. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther. 2018;182 : 152-160.

9. Hervé V, Rabbe N, Guilleminault L, et al. VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating mutations. MAbs. 2014;6 : 1638-1648.

10. Parray HA, Shukla S, Perween R, et al. Inhalation monoclonal antibody therapy: A new way to treat and manage respiratory infections. Appl Microbiol Biotechnol. 2021;105 : 6315-6332.

11. AlOmeir O, Alhowail AH, Rabbani SI, et al. Safety and efficacy of tocilizumab in COVID-19: A systematic evaluation of adverse effects and therapeutic outcomes. J Infect Public Health. 2025;18 : 102873.

12. He X, Zou J, Zhang W, et al. Pulmonary inhaled drug delivery systems: From bench to bedside. J Control Release. 2025;388 : 114296.

13. Pouwels SD, Burgess JK, Verschuuren E, et al. The cellular composition of the lung lining fluid gradually changes from bronchus to alveolus. Respir Res. 2021;22 : 285.

14. Guo Y, Bera H, Shi C, et al. Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. Acta Pharm Sin B. 2021;11 : 2565-2584.

15. Matthews AA, Ee PLR, Ge R. Developing inhaled protein therapeutics for lung diseases. Mol Biomed. 2020;1 : 11.

16. Qin L, Cui Z, Wu Y, et al. Challenges and strategies to enhance the systemic absorption of inhaled peptides and proteins. Pharm Res. 2023;40 : 1037-1055.

17. Radivojev S, Kargl L, Pinto JT, et al. Integration of mucus and its impact within in vitro setups for inhaled drugs and formulations: Identifying the limits of simple vs. complex methodologies when studying drug dissolution and permeability. Int J Pharm. 2024;661 : 124455.

18. Hill DB, Button B, Rubinstein M, et al. Physiology and pathophysiology of human airway mucus. Physiol Rev. 2022;102 : 1757-1836.

19. Zheng B, Liu D, Qin X, et al. Mucoadhesive-to-mucopenetrating nanoparticles for mucosal drug delivery: A mini review. Int J Nanomedicine. 2025;20 : 2241-2252.

20. Liu Q, Zhang X, Xue J, et al. Exploring the intrinsic micro-/nanoparticle size on their in vivo fate after lung delivery. J Control Release. 2022;347 : 435-448.

21. Patel B, Gupta N, Ahsan F. Particle engineering to enhance or lessen particle uptake by alveolar macrophages and to influence the therapeutic outcome. Eur J Pharm Biopharm. 2015;89 : 163-174.

22. Loo CY, Siew EL, Young PM, et al. Toxicity of curcumin nanoparticles towards alveolar macrophage: Effects of surface charges. Food Chem Toxicol. 2022;163 : 112976.

23. Possmayer F, Zuo YY, Veldhuizen RAW, et al. Pulmonary surfactant: A mighty thin film. Chem Rev. 2023;123 : 13209-13290.

24. Watson A, Madsen J, Clark HW. SP-A and SP-D: Dual functioning immune molecules with antiviral and immunomodulatory properties. Front Immunol. 2021;11 : 622598.

25. Kim CY, Chung SH, Choi YS, et al. Evaluating novel SP-B and SP-C synthetic analogues for pulmonary surfactant efficacy. Int J Med Sci. 2024;21 : 775-783.

26. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev. 2012;64 : 116-127.

27. Harijan ???, Singh ???. Zwitterionic polymers in drug delivery: A review [Internet]. ???; 2022 [cited ???]. Available from: ???

28. Roque C, Sheung A, Rahman N, et al. Effect of polyethylene glycol conjugation on conformational and colloidal stability of a monoclonal antibody antigen-binding fragment (Fab΄). Mol Pharm. 2015;12 : 562-575.

29. Guichard MJ, Leal T, Vanbever R. PEGylation, an approach for improving the pulmonary delivery of biopharmaceuticals. Curr Opin Colloid Interface Sci. 2017;31 : 43-50.

30. Baumann A, Tuerck D, Prabhu S, et al. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: Quo vadis? Drug Discov Today. 2014;19 : 1623-1631.

31. Youn YS, Kwon MJ, Na DH, et al. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: Optimization by PEG size selection. J Control Release. 2008;125 : 68-75.

32. Japiassu KB, Fay F, Marengo A, et al. Interplay between mucus mobility and alveolar macrophage targeting of surface-modified liposomes. J Control Release. 2022;352 : 15-24.

33. Li J, Wang X, Zhang T, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci. 2015;10 : 81-98.

34. Tsao C, Yuan Z, Zhang P, et al. Enhanced pulmonary systemic delivery of protein drugs via zwitterionic polymer conjugation. J Control Release. 2020;322 : 170-176.

35. Blackman LD, Gunatillake PA, Cass P, et al. An introduction to zwitterionic polymer behavior and applications in solution and at surfaces. Chem Soc Rev. 2019;48 : 757-770.

36. Yamamoto A, Ukai H, Morishita M, et al. Approaches to improve intestinal and transmucosal absorption of peptide and protein drugs. Pharmacol Ther. 2020;211 : 107537.

37. Amancha KP, Hussain A. Effect of protease inhibitors on pulmonary bioavailability of therapeutic proteins and peptides in the rat. Eur J Pharm Sci. 2015;68 : 1-10.

38. Park SH, Kwon JH, Lim SH, et al. Characterization of human insulin microcrystals and their absorption enhancement by protease inhibitors in rat lungs. Int J Pharm. 2007;339 : 205-212.

39. Garcia-Verdugo I, Descamps D, Chignard M, et al. Lung protease/anti-protease network and modulation of mucus production and surfactant activity. Biochimie. 2010;92 : 1608-1617.

40. Codrons V, Vanderbist F, Ucakar B, et al. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J Pharm Sci. 2004;93 : 1241-1252.

41. Gao Y, Sun Y, Liao G, et al. DSPE-PEG polymers for improving pulmonary absorption of poorly absorbed macromolecules in rats and relative mechanism. Drug Dev Ind Pharm. 2021;47 : 337-346.

42. Chono S, Togami K, Itagaki S. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary absorption of encapsulated insulin compared with co-administered insulin. Drug Dev Ind Pharm. 2017;43 : 1892-1898.

43. Ghadiri M, Canney F, Pacciana C, et al. The use of fatty acids as absorption enhancer for pulmonary drug delivery. Int J Pharm. 2018;541 : 93-100.

44. Johansson F, Hjertberg E, Eirefelt S, et al. Mechanisms for absorption enhancement of inhaled insulin by sodium taurocholate. Eur J Pharm Sci. 2002;17 : 63-71.

45. Del Vecchio G, Tscheik C, Tenz K, et al. Sodium caprate transiently opens claudin-5-containing barriers at tight junctions of epithelial and endothelial cells. Mol Pharm. 2012;9 : 2523-2533.

46. Ghadiri M, Mamlouk M, Spicer P, et al. Effect of polyunsaturated fatty acids (PUFAs) on airway epithelial cells’ tight junction. Pulm Pharmacol Ther. 2016;40 : 30-38.

47. Miyake M, Minami T, Yamazaki H, et al. Arachidonic acid with taurine enhances pulmonary absorption of macromolecules without any serious histopathological damages. Eur J Pharm Biopharm. 2017;114 : 22-28.

48. Farshbaf M, Davaran S, Zarebkohan A, et al. Significant role of cationic polymers in drug delivery systems. Artif Cells Nanomed Biotechnol. 2018;46 : 1872-1891.

49. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev. 2010;62 : 12-27.

50. Amidi M, Mastrobattista E, Jiskoot W, et al. Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliv Rev. 2010;62 : 59-82.

51. Lemmer HJ, Hamman JH. Paracellular drug absorption enhancement through tight junction modulation. Expert Opin Drug Deliv. 2013;10 : 103-114.

52. Florea BI, Thanou M, Junginger HE, et al. Enhancement of bronchial octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation. J Control Release. 2006;110 : 353-361.

53. Zhang H, Huang X, Sun Y, et al. Absorption-improving effects of chitosan oligomers based on their mucoadhesive properties: A comparative study on the oral and pulmonary delivery of calcitonin. Drug Deliv. 2016;23 : 2419-2427.

54. Hussain A, Arnold JJ, Khan MA, et al. Absorption enhancers in pulmonary protein delivery. J Control Release. 2004;94 : 15-24.

55. Hussain A, Yang T, Zaghloul AA, et al. Pulmonary absorption of insulin mediated by tetradecyl-β-maltoside and dimethyl-β-cyclodextrin. Pharm Res. 2003;20 : 1551-1557.

56. Nakate T, Yoshida H, Ohike A, et al. Improvement of pulmonary absorption of cyclopeptide FK224 in rats by co-formulating with β-cyclodextrin. Eur J Pharm Biopharm. 2003;55 : 147-154.

57. Sakagami M. Systemic delivery of biotherapeutics through the lung: Opportunities and challenges for improved lung absorption. Ther Deliv. 2013;4 : 1511-1525.

58. Liang W, Pan HW, Vllasaliu D, et al. Pulmonary delivery of biological drugs. Pharmaceutics. 2020;12 : 1025.

59. Unverdorben F, Richter F, Hutt M, et al. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. MAbs. 2016;8 : 120-128.

60. Sakagami M, Omidi Y, Campbell L, et al. Expression and transport functionality of FcRn within rat alveolar epithelium: A study in primary cell culture and in the isolated perfused lung. Pharm Res. 2006;23 : 270-279.

61. Bitonti AJ, Dumont JA, Low SC, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A. 2004;101 : 9763-9768.

62. Vallee S, Rakhe S, Reidy T, et al. Pulmonary administration of interferon beta-1a-Fc fusion protein in non-human primates using an immunoglobulin transport pathway. J Interferon Cytokine Res. 2012;32 : 178-184.

Další literatura na webu
a u autora.